Clovis Oncology Inc expected to post a loss of 41 cents a share - Earnings Preview

Clovis Oncology

28/10/2022 19:15

* Clovis Oncology Inc  CLVS.OQ   CLVS.O  is expected to show
a
fall in quarterly revenue when it reports  results on November 1
(estimated). 
    * The Boulder Colorado-based  company is expected to report 
a
12.4% decrease in revenue to $33.221 million from $37.92 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Clovis Oncology Inc
is
for a loss of 41 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Clovis
Oncology
Inc is $2​, above​ its last closing price of $1.04. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.42       -0.41      -0.50     Missed  -21
 Mar. 31 2022  -0.43       -0.43      -0.44     Missed  -1.7
 Dec. 31 2021  -0.55       -0.57      -0.48     Beat    15.8​
 Sep. 30 2021  -0.47       -0.48      -0.56     Missed  -17.2
 ​​Jun.        -0.55       -0.56      -0.61     Missed  -8
 30 2021                                                
 Mar. 31 2021  -0.73       -0.72      -0.64     Beat    10.9​
 Dec. 31 2020  -0.76       -0.77      -1.02     Missed  -32.5
 Sep. 30 2020  -0.98       -0.99      -0.89     Beat    10.3
 This summary was machine generated October 28 at 18:15 GMT.  All
figures in US dollars  unless otherwise stated